How the glucocorticoid receptor contributes to platinum-based therapy resistance in solid cancer
- Author
- Dorien Clarisse (UGent) and Karolien De Bosscher (UGent)
- Organization
- Abstract
- Synthetic glucocorticoids serve as co-medication against solid malignant tumors. However, glucocorticoid receptor activation may promote unsolicited cancer resistance to chemotherapy. The Kang team elucidated a glucocorticoid receptor-centred chemotherapy-resistance mechanism to cisplatin and characterized avenues towards a viable escape strategy.
- Keywords
- General Physics and Astronomy, General Biochemistry, Genetics and Molecular Biology, General Chemistry, DEXAMETHASONE, MECHANISMS
Downloads
-
Clarisse en De Bosscher - 2021 - How the glucocorticoid receptor contributes to pla.pdf
- full text (Published version)
- |
- open access
- |
- |
- 283.85 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8749033
- MLA
- Clarisse, Dorien, and Karolien De Bosscher. “How the Glucocorticoid Receptor Contributes to Platinum-Based Therapy Resistance in Solid Cancer.” NATURE COMMUNICATIONS, vol. 12, no. 1, 2021, doi:10.1038/s41467-021-24847-6.
- APA
- Clarisse, D., & De Bosscher, K. (2021). How the glucocorticoid receptor contributes to platinum-based therapy resistance in solid cancer. https://doi.org/10.1038/s41467-021-24847-6
- Chicago author-date
- Clarisse, Dorien, and Karolien De Bosscher. 2021. “How the Glucocorticoid Receptor Contributes to Platinum-Based Therapy Resistance in Solid Cancer.” NATURE COMMUNICATIONS. https://doi.org/10.1038/s41467-021-24847-6.
- Chicago author-date (all authors)
- Clarisse, Dorien, and Karolien De Bosscher. 2021. “How the Glucocorticoid Receptor Contributes to Platinum-Based Therapy Resistance in Solid Cancer.” NATURE COMMUNICATIONS. doi:10.1038/s41467-021-24847-6.
- Vancouver
- 1.Clarisse D, De Bosscher K. How the glucocorticoid receptor contributes to platinum-based therapy resistance in solid cancer. Vol. 12, NATURE COMMUNICATIONS. 2021.
- IEEE
- [1]D. Clarisse and K. De Bosscher, “How the glucocorticoid receptor contributes to platinum-based therapy resistance in solid cancer,” NATURE COMMUNICATIONS, vol. 12, no. 1. 2021.
@misc{8749033,
abstract = {{Synthetic glucocorticoids serve as co-medication against solid malignant tumors. However, glucocorticoid receptor activation may promote unsolicited cancer resistance to chemotherapy. The Kang team elucidated a glucocorticoid receptor-centred chemotherapy-resistance mechanism to cisplatin and characterized avenues towards a viable escape strategy.}},
articleno = {{4959}},
author = {{Clarisse, Dorien and De Bosscher, Karolien}},
issn = {{2041-1723}},
keywords = {{General Physics and Astronomy,General Biochemistry,Genetics and Molecular Biology,General Chemistry,DEXAMETHASONE,MECHANISMS}},
language = {{eng}},
number = {{1}},
pages = {{3}},
series = {{NATURE COMMUNICATIONS}},
title = {{How the glucocorticoid receptor contributes to platinum-based therapy resistance in solid cancer}},
url = {{http://doi.org/10.1038/s41467-021-24847-6}},
volume = {{12}},
year = {{2021}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: